Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 158

1.

Activation of proteinase 3 contributes to Non-alcoholic Fatty Liver Disease (NAFLD) and insulin resistance.

Toonen EJ, Mirea AM, Tack CJ, Stienstra R, Ballak DB, van Diepen JA, Hijmans A, Chavakis T, Dokter WH, Pham CT, Netea MG, Dinarello CA, Joosten LA.

Mol Med. 2016 May 24;22. doi: 10.2119/molmed.2016.00033.

2.

APOC3 Protein Is Not a Predisposing Factor for Fat-induced Nonalcoholic Fatty Liver Disease in Mice.

Cheng X, Yamauchi J, Lee S, Zhang T, Gong Z, Muzumdar R, Qu S, Dong HH.

J Biol Chem. 2017 Mar 3;292(9):3692-3705. doi: 10.1074/jbc.M116.765917. Epub 2017 Jan 23.

3.

Metabolic phenotype and adipose and liver features in a high-fat Western diet-induced mouse model of obesity-linked NAFLD.

Luo Y, Burrington CM, Graff EC, Zhang J, Judd RL, Suksaranjit P, Kaewpoowat Q, Davenport SK, O'Neill AM, Greene MW.

Am J Physiol Endocrinol Metab. 2016 Mar 15;310(6):E418-39. doi: 10.1152/ajpendo.00319.2015. Epub 2015 Dec 15.

4.

Hepatic STAMP2 alleviates high fat diet-induced hepatic steatosis and insulin resistance.

Kim HY, Park SY, Lee MH, Rho JH, Oh YJ, Jung HU, Yoo SH, Jeong NY, Lee HJ, Suh S, Seo SY, Cheong J, Jeong JS, Yoo YH.

J Hepatol. 2015 Aug;63(2):477-85. doi: 10.1016/j.jhep.2015.01.025. Epub 2015 Jan 31.

PMID:
25646886
5.

Protective effect of quercetin on high-fat diet-induced non-alcoholic fatty liver disease in mice is mediated by modulating intestinal microbiota imbalance and related gut-liver axis activation.

Porras D, Nistal E, Martínez-Flórez S, Pisonero-Vaquero S, Olcoz JL, Jover R, González-Gallego J, García-Mediavilla MV, Sánchez-Campos S.

Free Radic Biol Med. 2017 Jan;102:188-202. doi: 10.1016/j.freeradbiomed.2016.11.037. Epub 2016 Nov 25.

PMID:
27890642
6.

Sake lees extract improves hepatic lipid accumulation in high fat diet-fed mice.

Kubo H, Hoshi M, Matsumoto T, Irie M, Oura S, Tsutsumi H, Hata Y, Yamamoto Y, Saito K.

Lipids Health Dis. 2017 Jun 3;16(1):106. doi: 10.1186/s12944-017-0501-y.

7.

Inflammatory arthritis in caspase 1 gene-deficient mice: contribution of proteinase 3 to caspase 1-independent production of bioactive interleukin-1beta.

Joosten LA, Netea MG, Fantuzzi G, Koenders MI, Helsen MM, Sparrer H, Pham CT, van der Meer JW, Dinarello CA, van den Berg WB.

Arthritis Rheum. 2009 Dec;60(12):3651-62. doi: 10.1002/art.25006.

8.

Non-alcoholic fatty liver disease, vascular inflammation and insulin resistance are exacerbated by TRAIL deletion in mice.

Cartland SP, Harith HH, Genner SW, Dang L, Cogger VC, Vellozzi M, Di Bartolo BA, Thomas SR, Adams LA, Kavurma MM.

Sci Rep. 2017 May 15;7(1):1898. doi: 10.1038/s41598-017-01721-4.

9.

Long-term fermented soybean paste improves metabolic parameters associated with non-alcoholic fatty liver disease and insulin resistance in high-fat diet-induced obese mice.

Kim MS, Kim B, Park H, Ji Y, Holzapfel W, Kim DY, Hyun CK.

Biochem Biophys Res Commun. 2018 Jan 8;495(2):1744-1751. doi: 10.1016/j.bbrc.2017.12.003. Epub 2017 Dec 6.

PMID:
29222051
10.

Neutrophil Proteases Promote Experimental Abdominal Aortic Aneurysm via Extracellular Trap Release and Plasmacytoid Dendritic Cell Activation.

Yan H, Zhou HF, Akk A, Hu Y, Springer LE, Ennis TL, Pham CTN.

Arterioscler Thromb Vasc Biol. 2016 Aug;36(8):1660-1669. doi: 10.1161/ATVBAHA.116.307786. Epub 2016 Jun 9.

11.

Elevated hepatic DPP4 activity promotes insulin resistance and non-alcoholic fatty liver disease.

Baumeier C, Schlüter L, Saussenthaler S, Laeger T, Rödiger M, Alaze SA, Fritsche L, Häring HU, Stefan N, Fritsche A, Schwenk RW, Schürmann A.

Mol Metab. 2017 Oct;6(10):1254-1263. doi: 10.1016/j.molmet.2017.07.016. Epub 2017 Aug 4.

12.

Glucoraphanin Ameliorates Obesity and Insulin Resistance Through Adipose Tissue Browning and Reduction of Metabolic Endotoxemia in Mice.

Nagata N, Xu L, Kohno S, Ushida Y, Aoki Y, Umeda R, Fuke N, Zhuge F, Ni Y, Nagashimada M, Takahashi C, Suganuma H, Kaneko S, Ota T.

Diabetes. 2017 May;66(5):1222-1236. doi: 10.2337/db16-0662. Epub 2017 Feb 16.

13.

Fructose as a key player in the development of fatty liver disease.

Basaranoglu M, Basaranoglu G, Sabuncu T, Sentürk H.

World J Gastroenterol. 2013 Feb 28;19(8):1166-72. doi: 10.3748/wjg.v19.i8.1166. Review.

14.

Short-term strength training reduces gluconeogenesis and NAFLD in obese mice.

Pereira RM, Rodrigues KCDC, Anaruma CP, Sant'Ana MR, de Campos TDP, Gaspar RS, Canciglieri RDS, de Melo DG, Mekary RA, da Silva ASR, Cintra DE, Ropelle ER, Pauli JR, de Moura LP.

J Endocrinol. 2019 Apr 1;241(1):59-70. doi: 10.1530/JOE-18-0567.

PMID:
30878016
15.

Cardiotrophin-1 eliminates hepatic steatosis in obese mice by mechanisms involving AMPK activation.

Castaño D, Larequi E, Belza I, Astudillo AM, Martínez-Ansó E, Balsinde J, Argemi J, Aragon T, Moreno-Aliaga MJ, Muntane J, Prieto J, Bustos M.

J Hepatol. 2014 May;60(5):1017-25. doi: 10.1016/j.jhep.2013.12.012. Epub 2013 Dec 19.

PMID:
24362075
16.

(S)YS-51, a novel isoquinoline alkaloid, attenuates obesity-associated non-alcoholic fatty liver disease in mice by suppressing lipogenesis, inflammation and coagulation.

Park EJ, Kim YM, Kim HJ, Jang SY, Oh MH, Lee DH, Chang KC.

Eur J Pharmacol. 2016 Oct 5;788:200-209. doi: 10.1016/j.ejphar.2016.06.040. Epub 2016 Jun 23.

PMID:
27343380
17.

Impact of glycosylphosphatidylinositol-specific phospholipase D on hepatic diacylglycerol accumulation, steatosis, and insulin resistance in diet-induced obesity.

Masuda S, Fujishima Y, Maeda N, Tsugawa-Shimizu Y, Nakamura Y, Tanaka Y, Obata Y, Fukuda S, Nagao H, Kita S, Nishizawa H, Shimomura I.

Am J Physiol Endocrinol Metab. 2019 Feb 1;316(2):E239-E250. doi: 10.1152/ajpendo.00319.2018. Epub 2018 Nov 20.

PMID:
30457913
18.

Imbalance between neutrophil elastase and its inhibitor α1-antitrypsin in obesity alters insulin sensitivity, inflammation, and energy expenditure.

Mansuy-Aubert V, Zhou QL, Xie X, Gong Z, Huang JY, Khan AR, Aubert G, Candelaria K, Thomas S, Shin DJ, Booth S, Baig SM, Bilal A, Hwang D, Zhang H, Lovell-Badge R, Smith SR, Awan FR, Jiang ZY.

Cell Metab. 2013 Apr 2;17(4):534-48. doi: 10.1016/j.cmet.2013.03.005.

19.

α-Mangostin ameliorates hepatic steatosis and insulin resistance by inhibition C-C chemokine receptor 2.

Kim HM, Kim YM, Huh JH, Lee ES, Kwon MH, Lee BR, Ko HJ, Chung CH.

PLoS One. 2017 Jun 9;12(6):e0179204. doi: 10.1371/journal.pone.0179204. eCollection 2017.

20.

High fat diet feeding results in gender specific steatohepatitis and inflammasome activation.

Ganz M, Csak T, Szabo G.

World J Gastroenterol. 2014 Jul 14;20(26):8525-34. doi: 10.3748/wjg.v20.i26.8525.

Supplemental Content

Support Center